Anna M. Szpurka

Blocking TIM-3 in Treatment-refractory Advanced Solid Tumors: A Phase Ia/b Study of LY3321367 with or without an Anti-PD-L1 Antibody

James J. Harding, Víctor Moreno, Yung‐Jue Bang et al. · Clinical Cancer Research · 2021 · 159 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors

Matthew D. Hellmann, Nicoletta Bivi, Boris Calderón et al. · Clinical Cancer Research · 2021 · 112 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Safety and Pharmacokinetics of CXCR4 Peptide Antagonist, LY2510924, in Combination with Durvalumab in Advanced Refractory Solid Tumors

Mark H. O’Hara, Wells A. Messersmith, Hedy L. Kindler et al. · Journal of Pancreatic Cancer · 2020 · 49 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

Amita Patnaik, Timothy A. Yap, Hyun Cheol Chung et al. · Clinical Cancer Research · 2020 · 47 citations · Full text

Medicine, Oncology, Pharmacology +17

LY3022855, an anti–colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial

Afshin Dowlati, R. Donald Harvey, Richard D. Carvajal et al. · Investigational New Drugs · 2021 · 45 citations

Pharmacy, Oncology, Pharmacotherapy +15